SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-280542"
 

Search: id:"swepub:oai:DiVA.org:uu-280542" > Expression of possi...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Delforoush, Maryam,1980-Uppsala universitet,Experimentell och klinisk onkologi,Gunilla Enblad (author)

Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • 2016-07-12
  • Wiley,2017
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-280542
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-280542URI
  • https://doi.org/10.1111/ejh.12784DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:135129191URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Objectives: Investigating expression of possible targets for proteasome inhibitors in patients with diffuse large B-cell lymphoma (DLBCL) and correlating the findings to clinical parameters and outcome.Methods: Tumour material from 92 patients with DLBCL treated with either R-CHOP like (n = 69) or CHOP like (n = 23) regimens were stained for possible targets of proteasome inhibitors.Results: The primary target molecule of bortezomib, proteasome subunit beta, type 5 (PSMB5), was not detected in the tumour cells in any of the cases but showed an abundant expression in cells in the microenvironment. However, the deubiquitinases (DUBs) of the proteasome, the ubiquitin carboxyl-terminal hydrolase L5 (UCHL5) and the ubiquitin specific peptidase 14 (USP14), were detected in the cytoplasm of the tumour cells in 77% and 74% of the cases, respectively. The adhesion regulating molecule 1 (ADRM1) was detected in 98% of the cases. There was no correlation between the expression of any of the studied markers and clinical outcome or GC/non-GC phenotype.Conclusions: We suggest that UCHL5 and/or USP14 should be further evaluated as new targets for proteasome inhibitors in DLBCL. The lack of expression of PSMB5 on the tumour cells might provide an explanation of the relatively poor results of bortezomib in DLBCL.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Berglund, MattiasKarolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)mattiber (author)
  • Edqvist, Per-HenrikUppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab(Swepub:uu)peedq227 (author)
  • Sundström, ChristerUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)chrisund (author)
  • Gullbo, JoachimUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)joacgull (author)
  • Enblad, GunillaUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)gunienbl (author)
  • Uppsala universitetExperimentell och klinisk onkologi (creator_code:org_t)

Related titles

  • In:European Journal of Haematology: Wiley98:1, s. 52-560902-44411600-0609

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view